AMED RSI Chart
Last 7 days
2.2%
Last 30 days
1.9%
Last 90 days
0.9%
Trailing 12 Months
27.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 2.3B | 0 | 0 | 0 |
2023 | 2.2B | 2.2B | 2.2B | 2.2B |
2022 | 2.2B | 2.2B | 2.2B | 2.2B |
2021 | 2.1B | 2.2B | 2.2B | 2.2B |
2020 | 2.0B | 2.0B | 2.0B | 2.1B |
2019 | 1.7B | 1.8B | 1.9B | 2.0B |
2018 | 1.5B | 1.6B | 1.6B | 1.7B |
2017 | 1.5B | 1.5B | 1.5B | 1.5B |
2016 | 1.3B | 1.4B | 1.4B | 1.4B |
2015 | 1.2B | 1.2B | 1.2B | 1.3B |
2014 | 1.2B | 1.2B | 1.2B | 1.2B |
2013 | 1.4B | 1.4B | 1.3B | 1.2B |
2012 | 1.5B | 1.5B | 1.5B | 1.4B |
2011 | 1.6B | 1.5B | 1.5B | 1.5B |
2010 | 1.5B | 1.6B | 1.6B | 1.6B |
2009 | 1.3B | 1.4B | 1.4B | 1.5B |
2008 | 0 | 861.1M | 1.0B | 1.2B |
2007 | 0 | 0 | 0 | 697.9M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 03, 2024 | samuels ivanetta davis | acquired | - | - | 1,678 | - |
May 03, 2024 | kline teresa l. | acquired | - | - | 1,678 | - |
May 03, 2024 | coye molly joel | acquired | - | - | 1,678 | - |
May 03, 2024 | klapstein julie d | acquired | - | - | 1,678 | - |
May 03, 2024 | perkins bruce d | acquired | - | - | 1,678 | - |
May 03, 2024 | kusserow paul b. k. | acquired | - | - | 1,678 | - |
May 03, 2024 | guidroz allyson | sold (taxes) | -26,058 | 92.08 | -283 | chief accounting officer |
May 03, 2024 | rideout jeffrey a | acquired | - | - | 1,678 | - |
May 03, 2024 | capps vickie l | acquired | - | - | 1,678 | - |
Feb 20, 2024 | north michael paul | sold (taxes) | -149,061 | 93.69 | -1,591 | chief information officer |
Which funds bought or sold AMED recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 08, 2024 | Russell Investments Group, Ltd. | reduced | -92.42 | -1,809,910 | 143,492 | -% |
May 08, 2024 | GREAT LAKES ADVISORS, LLC | added | 0.59 | -321,628 | 12,659,000 | 0.11% |
May 08, 2024 | US BANCORP \DE\ | reduced | -2.78 | -24,778 | 406,795 | -% |
May 08, 2024 | MRP Capital Investments, LLC | reduced | -4.37 | -137,124 | 1,744,590 | 1.75% |
May 08, 2024 | BCK Capital Management LP | sold off | -100 | -1,378,370 | - | -% |
May 08, 2024 | COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | added | 0.25 | -19,224 | 665,303 | -% |
May 08, 2024 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | added | 5.27 | -643,248 | 2,824,540 | 0.01% |
May 08, 2024 | Calamos Advisors LLC | added | 47.09 | 9,805,690 | 32,820,700 | 0.16% |
May 08, 2024 | KBC Group NV | unchanged | - | -1,000 | 40,000 | -% |
May 08, 2024 | Cetera Trust Company, N.A | reduced | -19.91 | -48,026 | 166,810 | 0.10% |
Unveiling Amedisys Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Amedisys Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 466.7B | 379.5B | 30.38 | 1.23 | ||||
CI | 99.7B | 206.0B | 25.87 | 0.48 | ||||
HCA | 84.3B | 66.7B | 15.4 | 1.26 | ||||
CVS | 69.9B | 360.9B | 9.54 | 0.19 | ||||
CNC | 41.4B | 155.5B | 15.15 | 0.27 | ||||
DVA | 12.1B | 12.3B | 14.83 | 0.98 | ||||
UHS | 11.9B | 14.7B | 14.57 | 0.81 | ||||
MID-CAP | ||||||||
CHE | 8.7B | 2.3B | 30.66 | 3.79 | ||||
ACHC | 6.5B | 3.0B | -579.28 | 2.19 | ||||
AMN | 2.3B | 3.8B | 10.95 | 0.61 | ||||
AMEH | 2.2B | 1.5B | 35.09 | 1.51 | ||||
SMALL-CAP | ||||||||
ADUS | 1.7B | 1.1B | 26.48 | 1.6 | ||||
BKD | 1.4B | 3.0B | -7.95 | 0.45 | ||||
BEAT | 53.2M | - | -3.52 | - | ||||
AMS | 19.4M | 21.3M | 36.34 | 0.91 |
Amedisys Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 0.1% | 571 | 571 | 556 | 553 | 556 | 562 | 558 | 558 | 545 | 559 | 553 | 564 | 537 | 551 | 544 | 485 | 492 | 501 | 495 | 493 | 467 |
Costs and Expenses | 0.6% | 540 | 537 | 514 | 515 | 514 | 516 | 519 | 510 | 497 | 511 | 497 | 491 | 477 | 495 | 486 | 458 | 448 | 459 | 448 | 448 | 423 |
EBITDA Margin | -5.5% | 0.04* | 0.04* | 0.04* | 0.04* | 0.09* | 0.09* | 0.10* | 0.11* | 0.13* | 0.14* | 0.15* | 0.16* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -1.4% | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 8.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 |
Income Taxes | 23.6% | 13.00 | 10.00 | 12.00 | 18.00 | 10.00 | 10.00 | 9.00 | 11.00 | 12.00 | 13.00 | 11.00 | 29.00 | 18.00 | 16.00 | -10.20 | 10.00 | 9.00 | 11.00 | 10.00 | 10.00 | 11.00 |
Earnings Before Taxes | -6.8% | 27.00 | 29.00 | 38.00 | -62.23 | 35.00 | 41.00 | 35.00 | 40.00 | 44.00 | 47.00 | 56.00 | 109 | 68.00 | 62.00 | 62.00 | 45.00 | 41.00 | 39.00 | 44.00 | 44.00 | 42.00 |
EBT Margin | -18.9% | 0.01* | 0.02* | 0.02* | 0.02* | 0.07* | 0.07* | 0.07* | 0.08* | 0.12* | 0.13* | 0.13* | 0.14* | - | - | - | - | - | - | - | - | - |
Net Income | -25.5% | 14.00 | 19.00 | 26.00 | -80.28 | 25.00 | 32.00 | 26.00 | 30.00 | 32.00 | 34.00 | 45.00 | 80.00 | 50.00 | 45.00 | 72.00 | 35.00 | 32.00 | 28.00 | 34.00 | 34.00 | 31.00 |
Net Income Margin | -111.3% | -0.01* | 0.00* | 0.00* | 0.00* | 0.05* | 0.05* | 0.05* | 0.06* | 0.09* | 0.09* | 0.10* | 0.11* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -115.8% | -9.21 | 58.00 | -10.83 | 59.00 | 25.00 | 39.00 | -15.19 | 56.00 | 48.00 | 4.00 | 60.00 | 67.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 1.4% | 2,090 | 2,060 | 2,027 | 1,982 | 1,947 | 1,976 | 1,982 | 2,001 | 1,908 | 1,857 | 1,938 | 1,600 | 1,573 | 1,567 | 1,603 | 1,645 | 1,440 | 1,263 | 1,212 | 1,206 | 1,184 |
Current Assets | 5.9% | 526 | 497 | 467 | 427 | 406 | 389 | 389 | 395 | 392 | 357 | 433 | 391 | 380 | 362 | 411 | 450 | 468 | 351 | 300 | 276 | 272 |
Cash Equivalents | -14.5% | 108 | 127 | 78.00 | 95.00 | 69.00 | 54.00 | 31.00 | 49.00 | 71.00 | 46.00 | 128 | 93.00 | 78.00 | 83.00 | 115 | 180 | 178 | 96.00 | 21.00 | 14.00 | 11.00 |
Net PPE | 2.0% | 43.00 | 42.00 | 40.00 | 36.00 | 33.00 | 16.00 | 17.00 | 18.00 | 17.00 | 18.00 | 20.00 | 21.00 | 22.00 | 24.00 | 24.00 | 25.00 | 26.00 | 28.00 | 30.00 | 30.00 | 30.00 |
Goodwill | 0% | 1,245 | 1,245 | 1,245 | 1,245 | 1,245 | 1,287 | 1,285 | 1,290 | 9.00 | 1,196 | 1,188 | 937 | 933 | 933 | 931 | 937 | 721 | 659 | 660 | 665 | 650 |
Liabilities | 0.7% | 947 | 940 | 934 | 922 | 814 | 870 | 913 | 962 | 888 | 881 | 989 | 724 | 784 | 756 | 845 | 923 | 760 | 621 | 609 | 643 | 663 |
Current Liabilities | 2.4% | 485 | 474 | 468 | 462 | 353 | 356 | 367 | 427 | 380 | 374 | 454 | 449 | 456 | 456 | 437 | 442 | 316 | 327 | 315 | 313 | 297 |
Long Term Debt | -1.6% | 356 | 362 | 367 | 370 | 373 | 419 | 443 | 442 | 429 | 432 | 435 | 179 | 231 | 205 | 301 | 393 | 380 | 232 | 232 | 266 | 304 |
LT Debt, Current | 2.5% | 37.00 | 36.00 | - | - | - | - | - | - | - | - | - | - | - | 10.00 | - | - | - | 10.00 | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 205 | - | - | - | 232 | - | - | - |
Shareholder's Equity | 2.0% | 1,088 | 1,067 | 1,040 | 1,061 | 1,133 | 1,107 | 1,070 | 1,039 | 1,021 | 976 | 949 | 876 | 790 | 811 | 758 | 722 | 680 | 642 | 603 | 563 | 521 |
Retained Earnings | 1.9% | 762 | 748 | 729 | 703 | 783 | 758 | 726 | 700 | 671 | 639 | 605 | 560 | 480 | 430 | 385 | 313 | 278 | 246 | 219 | 185 | 151 |
Additional Paid-In Capital | 1.0% | 795 | 787 | 777 | 769 | 759 | 755 | 751 | 743 | 737 | 728 | 721 | 714 | 707 | 698 | 690 | 666 | 656 | 645 | 635 | 623 | 614 |
Accumulated Depreciation | 3.9% | 96.00 | 92.00 | 94.00 | 91.00 | 105 | 101 | 102 | 100 | 99.00 | 97.00 | 100 | 99.00 | 98.00 | 95.00 | 102 | 101 | 98.00 | 96.00 | 101 | 99.00 | 97.00 |
Shares Outstanding | 0.0% | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | 2.3% | 54.00 | 53.00 | 54.00 | 54.00 | 54.00 | 55.00 | 54.00 | 53.00 | 54.00 | 45.00 | 44.00 | 2.00 | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Float | - | - | - | - | 2,600 | - | - | - | 3,000 | - | - | - | 6,900 | - | - | - | 5,500 | - | - | - | 2,800 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -110.8% | -6,541 | 60,311 | -9,843 | 60,759 | 25,961 | 40,883 | -13,630 | 57,409 | 48,621 | 5,166 | 61,767 | 67,958 | 54,002 | 65,912 | 83,083 | 133,922 | 6,035 | 75,220 | 47,455 | 59,266 | 20,059 |
Share Based Compensation | -16.1% | 7,886 | 9,400 | 7,243 | 9,108 | 3,273 | 610 | 3,495 | 5,148 | 7,347 | 5,940 | 4,397 | 6,156 | 7,307 | 6,972 | 7,124 | 6,725 | 5,909 | 6,589 | 6,298 | 5,538 | 6,615 |
Cashflow From Investing | -50.5% | -3,068 | -2,039 | -1,048 | -7,745 | 45,896 | -1,866 | -1,033 | -75,508 | -16,079 | -11,667 | -264,561 | -3,822 | -1,557 | -1,565 | -1,221 | -213,567 | -70,755 | -1,386 | -3,604 | -19,046 | -328,912 |
Cashflow From Financing | 36.3% | -8,550 | -13,425 | -6,254 | -10,953 | -56,890 | -16,344 | -2,641 | -4,046 | -7,402 | -75,938 | 238,356 | -49,834 | -57,458 | -96,443 | -146,736 | 82,160 | 146,042 | 1,899 | -36,996 | -36,872 | 299,178 |
Buy Backs | - | - | - | - | - | - | - | - | 17,351 | - | 14,999 | 10,805 | 1,188 | 72,886 | - | - | - | - | - | - | - | - |
CONSOLIDATED INCOME STATEMENT - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenues | $ 571,414 | $ 556,389 |
Cost of service, inclusive of depreciation | 321,537 | 315,010 |
General and administrative expenses: | ||
Salaries and benefits | 127,946 | 126,339 |
Non-cash compensation | 7,433 | 3,273 |
Merger-related expenses | 20,667 | 720 |
Depreciation and amortization | 4,271 | 4,443 |
Other | 57,941 | 64,225 |
Total operating expenses | 539,795 | 514,010 |
Operating income | 31,619 | 42,379 |
Other income (expense): | ||
Interest income | 1,727 | 406 |
Interest expense | (8,119) | (7,517) |
Equity in earnings from equity method investments | 910 | 123 |
Miscellaneous, net | 1,090 | (682) |
Total other expense, net | (4,392) | (7,670) |
Income before income taxes | 27,227 | 34,709 |
Income tax expense | (12,633) | (9,800) |
Net income | 14,594 | 24,909 |
Net (income) loss attributable to noncontrolling interests | (194) | 337 |
Net income attributable to Amedisys, Inc. | $ 14,400 | $ 25,246 |
Basic earnings per common share: | ||
Net income attributable to Amedisys, Inc. common stockholders | $ 0.44 | $ 0.78 |
Weighted average shares outstanding, basic (shares) | 32,670 | 32,558 |
Diluted earnings per common share: | ||
Net income attributable to Amedisys, Inc. common stockholders | $ 0.44 | $ 0.77 |
Weighted average shares outstanding, diluted (shares) | 32,979 | 32,643 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 108,234 | $ 126,450 |
Restricted cash | 12,470 | 12,413 |
Patient accounts receivable | 359,359 | 313,373 |
Prepaid expenses | 20,332 | 14,639 |
Other current assets | 26,053 | 30,060 |
Total current assets | 526,448 | 496,935 |
Property and equipment, net of accumulated depreciation of $96,056 and $92,422 | 42,684 | 41,845 |
Operating lease right of use assets | 88,425 | 88,939 |
Goodwill | 1,244,679 | 1,244,679 |
Intangible assets, net of accumulated amortization of $15,128 and $14,008 | 101,778 | 102,675 |
Other assets | 85,857 | 85,097 |
Total assets | 2,089,871 | 2,060,170 |
Current liabilities: | ||
Accounts payable | 36,249 | 28,237 |
Payroll and employee benefits | 131,631 | 136,835 |
Accrued expenses | 147,464 | 140,049 |
Termination fee paid by UnitedHealth Group | 106,000 | 106,000 |
Current portion of long-term obligations | 37,232 | 36,314 |
Current portion of operating lease liabilities | 26,284 | 26,286 |
Total current liabilities | 484,860 | 473,721 |
Long-term obligations, less current portion | 356,080 | 361,862 |
Operating lease liabilities, less current portion | 62,220 | 62,751 |
Deferred income tax liabilities | 43,229 | 40,635 |
Other long-term obligations | 828 | 1,418 |
Total liabilities | 947,217 | 940,387 |
Commitments and Contingencies—Note 7 | ||
Equity: | ||
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding | 0 | 0 |
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,146,546 and 38,131,478 shares issued; 32,676,115 and 32,667,631 shares outstanding | 38 | 38 |
Additional paid-in capital | 795,063 | 787,177 |
Treasury stock, at cost, 5,470,431 and 5,463,847 shares of common stock | (469,243) | (468,626) |
Retained earnings | 762,325 | 747,925 |
Total Amedisys, Inc. stockholders’ equity | 1,088,183 | 1,066,514 |
Noncontrolling interests | 54,471 | 53,269 |
Total equity | 1,142,654 | 1,119,783 |
Total liabilities and equity | $ 2,089,871 | $ 2,060,170 |
 | Mr. Richard M. Ashworth |
---|---|
 | amedisys.com |
 | Healthcare Plans |
 | 20000 |